查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552573

美國獸醫腫瘤市場規模、佔有率、趨勢分析報告：按治療方法、動物、癌症類型、細分市場預測，2024-2030 年

U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal (Canine, Feline), By Cancer Type (Skin Cancer, Lymphoma, Sarcomas), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國獸醫腫瘤學市場的成長和趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，美國獸用腫瘤市場規模將達到10.8億美元，2024年至2030年複合年成長率為10.76%。

寵物癌症盛行率不斷上升、寵物飼主願意為寵物花錢以及研究人員使用狗作為臨床試驗模型是推動市場成長的關鍵因素。此外，由於人們對寵物健康的日益關注，貓科動物癌症發病率的上升和寵物擁有量的增加預計也將刺激市場成長。此外，公司擴大採用併購、研究協議、聯盟、夥伴關係、地理擴張和產品開發等策略來增強其市場地位。

例如，2020年11月，Virbac宣布核准Stelfonta，一種治療犬肥大細胞腫瘤的新型腫瘤內注射療法。 Elanco 也收購了 Aratana Therapeutics，用於其寵物藥品管道。該公司還與 VetDC 簽訂了生產拉巴福嗪 (Tanovea) 的協議。此外，2021 年 7 月，Elanco 宣布 FDA 已完全核准Tanovea 用於治療犬淋巴瘤。因此，預計市場在預測期內將出現激烈競爭。伴同性動物癌症盛行率的不斷上升預計將推動對有效治療方案的需求。

在狗中，骨癌是一種極具侵襲性的疾病，治療方法包括化療，可以降低手術切除腫瘤以及隨後癌細胞擴散到其他部位（特別是肺部）的風險。據報道，金毛犬品種的癌症發生率比其他犬種更高。金毛獵犬是美國最受歡迎的犬種之一，人們對寵物健康的興趣日益濃厚，推動了市場的成長。臨床試驗是獸醫腫瘤學的一個重要方面。加速臨床研究（包括寵物手術）正在進一步推動市場成長。

例如，2019年5月，奧勒岡州立大學進行的一項研究表明，腫瘤被完全切除的狗癌症復發的風險降低了60%。隨著越來越多的美國養寵物，人們對動物健康的意識也越來越強。美國舉辦各種活動來傳播寵物健康意識，其中包括國家寵物週。人們認為動物將 COVID-19 傳播給個體的風險很小。 FDA 警告稱，COVID-19 大流行可能會影響正在進行的開發新藥研究。因此，2020年4月發布了指南，以減輕疫情對動物開發新藥的潛在影響。

美國獸醫腫瘤學市場報告亮點

  • 放射學領域預計將主導市場。政府加大舉措建立新的獸醫放射中心和放射技術的進步等因素預計將支持該領域的成長。
  • 隨著越來越多的獸醫院專注於免疫治療領域的臨床試驗，免疫治療領域預計將在 2023 年至 2030 年實現最快的複合年成長率。
  • 預計到 2030 年，化療將成為第二大治療領域。據癌症獸醫中心稱，最常見的接受化療的犬和貓腫瘤包括骨癌、淋巴瘤、血管肉瘤、肥大細胞腫瘤、膀胱腫瘤和乳腺腫瘤。
  • 2023 年，狗類細分市場佔據了最大的收益佔有率。狗的癌症高發病率和該領域持續的產品創新促進了該細分市場的成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國獸醫腫瘤學市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國獸醫腫瘤學市場分析工具
    • 波特的分析
    • PESTEL分析
  • COVID-19 分析
  • 主要國家的寵物數量估計

第4章美國獸醫腫瘤學市場：動物、估計與趨勢分析

  • 細分儀表板
  • 美國獸醫腫瘤市場波動分析
  • 2018-2030 年美國獸醫腫瘤市場規模及趨勢分析（以動物）
  • 狗
  • 貓
  • 馬

第5章美國獸醫腫瘤市場：治療方法、估計與趨勢分析

  • 細分儀表板
  • 美國獸醫腫瘤市場波動分析
  • 2018-2030 年美國獸醫腫瘤市場規模與趨勢分析（依治療方法）
  • 放射治療
  • 外科手術
  • 化療
  • 免疫療法
  • 其他

第6章美國獸醫腫瘤市場：癌症類型、估計與趨勢分析

  • 細分儀表板
  • 美國獸醫腫瘤市場波動分析
  • 2018-2030 年美國獸醫腫瘤學市場規模與趨勢分析（依癌症類型）
  • 皮膚癌
  • 淋巴瘤
  • 肉瘤
  • 其他

第7章 競爭格局

  • 市場參與企業分類
  • 企業市場分析/熱圖分析
  • 2023年企業市場佔有率評估分析
  • 策略規劃
    • 併購
    • 夥伴關係與協作
    • 其他
  • 公司簡介
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Zoetis
    • PetCure Oncology
    • Accuray Incorporated
    • Varian Medical Systems, Inc.
    • Elekta AB.
    • Karyopharm Therapeutics, Inc.
    • Virbac.
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • NovaVive Inc.
    • Ardent Animal Health, LLC（A BreakthrU Company）.

第8章 要點

Product Code: GVR-4-68039-370-4

U.S. Veterinary Oncology Market Growth & Trends:

The U.S. veterinary oncology market size is expected to reach USD 1.08 billion by 2030, registering a CAGR of 10.76% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.

For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.

In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.

For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.

U.S. Veterinary Oncology Market Report Highlights:

  • The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
  • The immunotherapy segment is estimated to register the fastest CAGR from 2023 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
  • Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
  • The canine segment accounted for the largest revenue share in 2023. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Research Scope and Assumptions
    • 1.7.1. List of Secondary Sources
    • 1.7.2. List of Primary Sources
    • 1.7.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing Prevalence Of Cancer In Pets
      • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3. Growing Focus On Animal Safety
      • 3.2.1.4. Growing Uptake Of Pet Insurance
      • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6. Increase In Pet Population
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Adverse effects associated with therapies
      • 3.2.2.3. Limited Clinical Evidence
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. U.S. Veterinary Oncology Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal landscape
  • 3.4. Covid-19 Analysis
  • 3.5. Estimated Pet Population, by key countries

Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Oncology Market Movement Analysis
  • 4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Canine
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Feline
    • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Equine
    • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Oncology Market Movement Analysis
  • 5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Radiotherapy
    • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Stereotactic Radiation Therapy
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.2. LINAC
        • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.3. Other Type
        • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Conventional Radiation Therapy
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapy
    • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunotherapy
    • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Therapies
    • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Oncology Market Movement Analysis
  • 6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
  • 6.4. Skin Cancer
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Lymphomas
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sarcomas
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Company Market Position Analysis/ Heat Map Analysis
  • 7.3. Estimated Company Market Share Analysis, 2023
  • 7.4. Strategy Mapping
    • 7.4.1. Mergers & Acquisitions
    • 7.4.2. Partnerships & Collaborations
    • 7.4.3. Others
  • 7.5. Company Profiles
    • 7.5.1. Elanco
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Zoetis
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. PetCure Oncology
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Accuray Incorporated
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Varian Medical Systems, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Elekta AB.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Karyopharm Therapeutics, Inc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Virbac.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Merck & Co., Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Dechra Pharmaceuticals PLC
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. NovaVive Inc.
      • 7.5.12.1. Participant's Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
      • 7.5.13.1. Participant's Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives

Chapter 8. Key Takeaways

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 4 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Company Overview
  • Table 7 Service Benchmarking
  • Table 8 Financial Performance
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 U.S. Veterinary Oncology Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of U.S. Veterinary Oncology Market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2023 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 U.S. Veterinary Oncology Market Dynamics
  • Fig. 18 Estimated animal population, 2018-2023 by key species and key countries
  • Fig. 19 U.S. Veterinary Oncology Market: PORTER's analysis
  • Fig. 20 U.S. Veterinary Oncology Market: PESTEL analysis
  • Fig. 21 U.S. Veterinary Oncology Market by Animal: Key Takeaways
  • Fig. 22 U.S. Veterinary Oncology Market by Animal, 2023 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Equine market, 2018 - 2030 (USD Million)
  • Fig. 26 Horses market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Veterinary Oncology Market by Therapy: Key Takeaways
  • Fig. 28 U.S. Veterinary Oncology Market by Therapy, Market Share, 2023 & 2030
  • Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 LINAC market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Veterinary Oncology Market by Cancer Type: Key Takeaways
  • Fig. 39 U.S. Veterinary Oncology Market by Cancer Type, Market Share, 2023 & 2030
  • Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
  • Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 43 Other market, 2018 - 2030 (USD Million)
  • Fig. 44 Market Participant Categorization
  • Fig. 45 Heat map analysis
  • Fig. 46 Strategic Framework